EUVIMEDEUVIMED entdecken
Crossref

Safety of Autologous Infusion of CER T Cells in Nonhuman Primates

Karsten Eichholz, Afam A Okoye iD, Benjamin D Varco-Merth, Jiaxin Gong, John Bui iD, Joe Hou, Hans-Peter Kiem, Daniel Hayball, Mark Hoenerhoff, Samuel T Robinson, Christopher W Peterson, Lawrence Corey iD und 1 weitere

AIDS Research and Human Retroviruses · 01.12.2026 · 42 (12) · 369-378

DOI: 10.1177/08892229261490969 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AIDS Research and Human Retroviruses, online erschienen am 07.10.2026. Verfasst von Karsten Eichholz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Simian Acquired Immunodeficiency Syndrome, T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Gilead HIV Cure Grant Program, National Institutes of Health Office of Research Infrastructure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cellular immunotherapies have shown great promise in the treatment of various diseases. Chimeric engulfment receptor (CER)-engineered T cells were developed to utilize the extracellular T-cell immunoglobulin and mucin domain-containing 4 (TIM-4) domain and intracellular engulfment signaling domains to target and enhance phagocytosis and T-cell cytotoxic function. These processes are activated through TIM-4 binding with phosphatidylserine (PS), a pro-phagocytic “eat me” signal. HIV infection has been shown to induce extracellular PS exposure shortly after infection, and engineered CER T cells have been shown to kill CD4 + T cells infected with simian immunodeficiency virus (SIV) in vitro . In this study, we infused two rhesus macaques (RMs) with CER-1236 T cells (the iteration of CER T cells currently moving forward in human clinical trials for cancer) and evaluated safety, the tissue distribution of the CER-1236 T cells, and antiviral activity against SIV (SIVmac239). Prior to infusions, RMs underwent SIV infection, antiretroviral therapy (ART), and ART cessation. The infusions were well tolerated. Neither of the macaques exhibited clinical evidence of illness nor changes in vital signs, serum chemistry, hematology, or other evaluated physiological parameters beyond what is typically observed with SIV infection. Post-infusion proliferation of CER T cells in PBMC was limited and seen with cells manufactured by the Prodigy system. Histologic and flow cytometry evaluation from post-infusion tissue biopsies and necropsy revealed tissue detection of CER T cells in bronchoalveolar lavage fluid with intermittent detection of infused cells in lymphoid tissue in concert with the limited expansion of T cells in PBMC. No laboratory or clinical evidence of hepatic, splenic, bone marrow, or CNS alterations was noted, and no evidence of in vivo suppression of SIVmac239 was observed as a result of the infusions. The CER-1236 T cell infusions were not associated with any discernable histopathological toxicity. This safety profile of CER-1236 T cells in nonhuman primates portends well for its potential for clinical development, especially for tumors with high expression of the tissue damage receptor PS. Optimization of in vivo functionality will be required for CER T cells to be effective against HIV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Simian Acquired Immunodeficiency SyndromeT-LymphocytesImmunotherapy, AdoptiveAnimalsMacaca mulattaSimian Immunodeficiency Virus

Stichwörter der Autor:innen

HIVcellular engineeringcellular therapyimmunotherapy

Autor:innen und Institutionen

  • Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, Oregon, USA.
  • Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Inotiv, Kalamazoo, Mississippi, USA.

ORCID-Profile: Afam A Okoye, John Bui, Lawrence Corey

Förderung

  • Gilead HIV Cure Grant Program
  • National Institutes of Health Office of Research Infrastructure

Zitieren

APA

Eichholz, K., Okoye, A. A., Varco-Merth, B. D., Gong, J., Bui, J., Hou, J., Kiem, H. P., Hayball, D., Hoenerhoff, M., Robinson, S. T., Peterson, C. W., Corey, L., & Corey, D. (2026). Safety of Autologous Infusion of CER T Cells in Nonhuman Primates. AIDS Research and Human Retroviruses, 42(12), 369-378. https://doi.org/10.1177/08892229261490969

Vancouver

Eichholz K, Okoye AA, Varco-Merth BD, Gong J, Bui J, Hou J, et al. Safety of Autologous Infusion of CER T Cells in Nonhuman Primates. AIDS Research and Human Retroviruses. 2026;42(12):369-378. doi:10.1177/08892229261490969

BibTeX
@article{Eichholz2026,
  author = {Eichholz, Karsten and Okoye, Afam A and Varco-Merth, Benjamin D and Gong, Jiaxin and Bui, John and Hou, Joe and Kiem, Hans-Peter and Hayball, Daniel and Hoenerhoff, Mark and Robinson, Samuel T and Peterson, Christopher W and Corey, Lawrence and Corey, Daniel},
  title = {Safety of Autologous Infusion of CER T Cells in Nonhuman Primates},
  journal = {AIDS Research and Human Retroviruses},
  year = {2026},
  volume = {42},
  number = {12},
  pages = {369--378},
  doi = {10.1177/08892229261490969}
}
Kostenlos starten →